Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2025	Sep. 30, 2024	Sep. 30, 2025	Sep. 30, 2024
Operating expenses:
Research and development	$ 30,106	$ 53,206	$ 97,056	$ 170,528
Research and development related success payments and contingent consideration	3,124	(5,497)	15,343	4,566
General and administrative	10,285	14,052	32,110	46,763
Impairment of long-lived assets			44,611
Total operating expenses	43,515	61,761	189,120	221,857
Loss from operations	(43,515)	(61,761)	(189,120)	(221,857)
Interest income, net	1,003	2,579	2,572	8,815
Other income (expense), net	360	(742)	1,207	(4,648)
Net loss	$ (42,152)	$ (59,924)	$ (185,341)	$ (217,690)
Net loss per common share - basic	$ (0.16)	$ (0.25)	$ (0.75)	$ (0.95)
Net loss per common share - diluted	$ (0.16)	$ (0.25)	$ (0.75)	$ (0.95)
Weighted-average number of common shares - basic	260,494	235,412	245,580	229,076
Weighted-average number of common shares - diluted	260,494	235,412	245,580	229,076